News
We bring you up to date at all times: Discover the latest industry news from biotechnology, pharmaceuticals and life sciences. Researched by us so you don't have to.
Selected departments
Selected industries
Companies
The Who's Who of Life Sciences: Discover companies from all over the world. Here you can easily find the provider matching your search, including contact options.
Selected countries
Selected companies
Products
The first stop for your procurement process: discover innovative products for lab and process that make your everyday life easier and solve even complex challenges.
Products of selected companies
Market overviews
Direct comparison of products for laboratory and process: Use the comprehensive market overviews to compare products according to your requirements and obtain further information from suppliers.
White papers
What could be better than an application problem that has already been solved by others? Tap into in-depth application knowledge from proven experts. Conveniently via download to your device.
Most read white papers
White papers of selected companies
Knowledge & education
Question. Answer. Find articles on 57,945 keywords in life science, biotech, pharma, biology and related science disciplines in the encyclopedia..
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Note
The function "Store search" is only available to registered users.
Important information
Currently, you are not logged in to my.bionity.com. Therefore, you can remember a maximum of 5 contents.
FILTER
Refine your search with the following facets to narrow down your results.
29-Nov-2010 - Basilea Pharmaceutica Ltd. announced that in consultation with the U.S. Food and Drug Administration (FDA) Basilea and its partner Astellas Pharma Inc. have agreed to use 'all-cause mortality' as the primary endpoint of the phase III clinical study investigating isavuconazole for the treatment of ...
24-Nov-2010 - Basilea Pharmaceutica Ltd. announces that the first phase I study of its innovative sulfactam antibiotic BAL30072 has been initiated. This study investigates the pharmacokinetic profile, safety and tolerability of the compound in healthy volunteers. BAL30072 has broad antimicrobial activity ...
04-Nov-2010 - Basilea Pharmaceutica Ltd. announces that it has received a milestone payment of EUR 5.5 million under its distribution agreement for Toctino® (alitretinoin) with Almirall, S.A. The milestone payment of EUR 5.5 million relates to Italy where Toctino® will become available in the coming weeks and ...
13-Sep-2010 - Basilea Pharmaceutica Ltd. announces that Janssen-Cilag AG, a Johnson & Johnson company, will be discontinuing sale of ceftobiprole (Zevtera(TM)) for the treatment of complicated skin and soft tissue infections (cSSTI) in Switzerland. Janssen-Cilag AG, the holder of the Marketing Authorization ...
29-Jun-2010 - Basilea Pharmaceutica Ltd. announces that following a request for re-examination from the Applicant Janssen-Cilag International NV, a Johnson & Johnson company, the European Committee for Medicinal Products for Human Use (CHMP) confirmed its previous negative opinion on the Marketing ...
29-Jun-2010 - Basilea Pharmaceutica Ltd. announced that its partner Astellas Pharma Inc.has initiated the formal process to allow continuation of patient recruitment into the phase III clinical studies of isavuconazole for the treatment of life-threatening invasive fungal infections. Certain study protocol ...
26-Feb-2010 - Basilea announced that Basilea Pharmaceutica International Ltd. has entered into a license, co-development and co-promotion agreement with Astellas Pharma Inc. for Basilea's azole antifungal agent isavuconazole in phase III clinical development for the treatment of life-threatening invasive ...
23-Feb-2010 - Basilea Pharmaceutica Ltd. announced that the European Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on the Marketing Authorization Application (MAA) for ceftobiprole for the treatment of complicated skin and soft tissue infections (cSSTI). The sponsor ...
02-Feb-2010 - Basilea Pharmaceutica Ltd. announced that based on a futility analysis of the isavuconazole phase III trial for the treatment of invasive Aspergillus infections, the Independent Data Safety Monitoring Board (IDSMB) has recommended the continuation of the study. The primary goal of this phase III ...
16-Jul-2009 - Basilea Pharmaceutica Ltd. announces that the National Institute for Health and Clinical Excellence (NICE) issued the Final Appraisal Determination (FAD) recommending the use of Toctino® (alitretinoin) within its licensed indication, as a treatment option for adults with severe chronic hand ...
© 1997-2024 LUMITOS AG, All rights reserved